Founded Year
2000Stage
Acquired | AcquiredTotal Raised
$9.45MAbout Combio
Developer of drugs based on genomic findings. The company focuses on the discovery and development of low molecular-weight drugs as well as peptide and peptidomimetic drugs. The company's drug discovery approach makes use of post genomic era opportunities for the design of improved drugs. The process is enhanced by the fact that there is a common feature to different classes of biological targets, so that each drug discovery effort benefits from the accumulated experience of previous programs that address similar targets.
Combio Headquarter Location
Vesterbrogade 188 / Frydendalsvej 32
Frederiksberg, 1800,
Denmark
45 70 222 365
Expert Collections containing Combio
Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.
Combio is included in 1 Expert Collection, including Omics.
Omics
1,265 items
Companies involved in the capture, sequencing, and/or analysis of genomic, transcriptomic, proteomic, and/or metabolomic data
Combio Patents
Combio has filed 1 patent.
The 3 most popular patent topics include:
- Clusters of differentiation
- Experimental cancer drugs
- Immune system
Application Date | Grant Date | Title | Related Topics | Status |
|---|---|---|---|---|
4/9/2018 | 5/10/2022 | Monoclonal antibodies, Experimental cancer drugs, Clusters of differentiation, Tyrosine kinase receptors, Immune system | Grant |
Application Date | 4/9/2018 |
|---|---|
Grant Date | 5/10/2022 |
Title | |
Related Topics | Monoclonal antibodies, Experimental cancer drugs, Clusters of differentiation, Tyrosine kinase receptors, Immune system |
Status | Grant |
Latest Combio News
Jan 27, 2021
publication date: Jan 27, 2021 Sihuan Pharma will acquire Beijing Combio Pharma for an undisclosed price. An innovative biopharma, Combio is developing 12 preclinical molecules that it discovered using its two antibody platforms: Mab Edit (antibody editing) and Mebs-Ig (antibody editing for bispecific antibodies). Combio will become part of Sihuan's existing novel drug development company, Xuanzhu Biopharm. In August 2020, Xuanzhu raised $148 million in venture capital at a $700 million valuation.
Discover the right solution for your team
The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.